Equity trader on Orphazyme surprise: "It's a bit like Gamestop all over again"

Orphazyme's share price has taken a wild ride over the past day – both in the US and Denmark. According to Mads Zink, head of Danish Cash Equities at Danske Bank, a Gamestop effect is happening.

Photo: Jens Dresling

Orphazyme trended on social media in the US on Thursday as its share price rocketed for no clear reason.

The biotech company has also attracted attention in Denmark, where the share price rose by 40 percent up to DKK 47.6 on Friday – a significant increase, but far less than the rise in the US.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs